Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma : A meta-analysis
© 2022 The Authors. World Journal of Otorhinolaryngology ‐ Head and Neck Surgery published by John Wiley & Sons Ltd on behalf of Chinese Medical Association..
Background: PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).
Methods: Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression-free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment-related adverse events (TRAEs).
Results: Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18-90). The total mOS was 7.97 months (range: 6.0-16.5). Mean mPFS for all studies was 2.84 months (range: 1.9-6.5). PD-1 inhibitors had a lower rate of RECIST Progressive Disease than PD-L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29-49.06 vs. 56.79%, 95% CI: 49.18-64.19, P < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8-65.6) did not differ.
Conclusions: Meta-analysis shows the efficacy of PD-1 and PD-L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD-1 and PD-L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
World journal of otorhinolaryngology - head and neck surgery - 8(2022), 3 vom: 01. Sept., Seite 177-186 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Levy, Dylan A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Revised 08.04.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/wjo2.15 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34676159X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34676159X | ||
| 003 | DE-627 | ||
| 005 | 20231226032225.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/wjo2.15 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM34676159X | ||
| 035 | |a (NLM)36159902 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Levy, Dylan A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma |b A meta-analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.04.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. World Journal of Otorhinolaryngology ‐ Head and Neck Surgery published by John Wiley & Sons Ltd on behalf of Chinese Medical Association. | ||
| 520 | |a Background: PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC) | ||
| 520 | |a Methods: Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression-free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment-related adverse events (TRAEs) | ||
| 520 | |a Results: Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18-90). The total mOS was 7.97 months (range: 6.0-16.5). Mean mPFS for all studies was 2.84 months (range: 1.9-6.5). PD-1 inhibitors had a lower rate of RECIST Progressive Disease than PD-L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29-49.06 vs. 56.79%, 95% CI: 49.18-64.19, P < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8-65.6) did not differ | ||
| 520 | |a Conclusions: Meta-analysis shows the efficacy of PD-1 and PD-L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD-1 and PD-L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a disease progression | |
| 650 | 4 | |a head and neck neoplasms | |
| 650 | 4 | |a humanized | |
| 650 | 4 | |a meta‐analysis | |
| 650 | 4 | |a monoclonal | |
| 650 | 4 | |a squamous cell carcinoma of the neck | |
| 700 | 1 | |a Patel, Jaimin J |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Shaun A |e verfasserin |4 aut | |
| 700 | 1 | |a Nicholas Jungbauer, W |e verfasserin |4 aut | |
| 700 | 1 | |a Neskey, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Ezra E W |e verfasserin |4 aut | |
| 700 | 1 | |a Paulos, Chrystal M |e verfasserin |4 aut | |
| 700 | 1 | |a Kaczmar, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Knochelmann, Hannah M |e verfasserin |4 aut | |
| 700 | 1 | |a Day, Terry A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of otorhinolaryngology - head and neck surgery |d 2015 |g 8(2022), 3 vom: 01. Sept., Seite 177-186 |w (DE-627)NLM270620958 |x 2589-1081 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2022 |g number:3 |g day:01 |g month:09 |g pages:177-186 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/wjo2.15 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2022 |e 3 |b 01 |c 09 |h 177-186 | ||